Lonza announced the expansion of its peptides manufacturing capacities
03-May-2005
The investment is focused on several areas of Lonza's peptides and oligonucleotides (tides) large-scale cGMP manufacturing activities. To serve customers' demand for clinical trial material the construction of a new mid-scale tides plant is planned. Additional HPLC-purification and new lyophilization equipment as well as essential items of infrastructure will be installed.
Other news from the department manufacturing
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.